# A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity

> **NCT05712642** · PHASE3 · COMPLETED · sponsor: **Cairo University** · enrollment: 19 (actual)

## Conditions studied

- Retinopathy of Prematurity

## Interventions

- **DRUG:** Intravitreal Bevacizumab

## Key facts

- **NCT ID:** NCT05712642
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-01-28
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05712642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05712642, "A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05712642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*